Geneva: World Health Organization (WHO) said that Covaxin – Covid-19 vaccine developed by Bharat Biotech – is very suitable for low and medium-sized income countries because of easy storage requirements.
UN Body Health – which gave approval for Emergency Use List (EUT) from Covaxin on Wednesday – said that vaccine Bharat Biotech was found to have a 78 percent efficacy of Covid-19 severity, 14 days or more after the second dose.
“Covaxin is found to have a 78 percent efficacy of # Covid19 of any severity, 14 days or more after the second dose, and is very suitable for low and medium income countries because of easy storage requirements,” said in a tweet.
on Wednesday.
The procedure for recording the UN Emergency Emergency Emergency use of the UN body assesses vaccines based on procedures based on data reviewing on quality, safety, efficacy, risk management plans and conformity in low-income and medium-sized countries.
Vaccines are formulated from the SARS-COV-2 antigens that are not active and served in a single dose bottle and a multidose bottle 5, 10 and 20 doses.
Dr.
Poonam Khetrapal Singh, whose Southeast Asian regional director has congratulated India on the list of emergency use Bharat Biotech’s Covid-19 Covaxin on Wednesday.
“Happy India for an emergency use list from the original Covaxin # Covid19 vaccine produced,” Dr.
Singh said in a tweet.
The WHO panel previously looked for additional clarification from Covaxin producers, to conduct the final EUL risk assessment for the use of global vaccines.
Approval was conducted on recommendations from the Technical Advisory Group (tag) for the list of emergency use (tag-eul), an independent advisory panel that provides recommendations to whom it is in the Covid-19 vaccine can be registered for emergency use under EUL.
procedure.
Covaxin ‘is very suitable’ for low-income countries low because of easy storage requirements: Who
